$HELP

Helus Pharma (Nasdaq: HELP) appointed Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board. Donohue previously led HR at Intra-Cellular, which grew to 1,000+ employees before being acquired by Johnson & Johnson in April 2025. Durgam helped secure FDA approvals for CAPLYTA. The moves support Helus’ clinical and potential commercialization plans.

Helus Pharma (Nasdaq: HELP) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Cash was $166.4M. Net loss was $47.8M vs $24.6M a year earlier. The company said Phase 3 APPROACH enrollment for HLP003 in MDD is complete with topline data expected in Q4 2026, and a DDI study showed no meaningful PK interaction. It also completed a $50M underwritten offering in June 2026.

Helus Pharma (Nasdaq: HELP) appointed Michael Halstead, former President of Intra-Cellular Therapies, as CEO effective immediately. The company said the hire supports upcoming Phase 3 readouts for HLP003 in Major Depressive Disorder, with topline data expected in Q4 2026, and continued enrollment in a second study. Helus also cited its IP portfolio and FDA Breakthrough Therapy Designation for HLP003.

According to Cybin D/B/A Helus Pharma (HELP), it appointed Michael Halstead as Chief Executive Officer effective immediately. The company said Halstead has 25 years of industry experience, most recently as President of Intra-Cellular Therapies (ITCI). In Nasdaq pre-market, HELP shares were down 0.90% to $7.75 after Friday’s 3.93% decline.

Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.

Helus Pharma (NASDAQ:HELP) shares rose 12.4% after the company said it completed enrollment in its APPROACH Phase 3 trial of HLP003 for major depressive disorder. The study enrolled 223 adults; topline data are expected in Q4 2026. APPROACH is one of two pivotal trials, with EMBRACE ongoing.

Eli Lilly (NYSE: LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ: ATAI) for $6.75 per share in cash (about $2.8B) plus up to $2.50 per share in milestone-linked contingent value rights, totaling up to about $3.8B. The deal was approved by both boards and is expected to close in Q3. The article cites Helus Pharma (NASDAQ: HELP) Phase 3 readout in Q4 2026.

Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) said it closed a previously announced underwritten offering of 10,309,280 common shares at US$4.85 each, raising US$50 million in gross proceeds. Cantor and Barclays were joint bookrunners; Bloom Burton and Lucid were lead managers. Net proceeds will fund Phase 3 HLP003 (MDD) with data expected in Q4 2026, plus HLP004 and HLP005, and for working capital.

Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) said interim CEO Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026 at 2:35 p.m. EDT. The webcast will be available live, with a replay on the company’s investor relations site.

PRISM MarketView highlighted seven public companies developing mental health therapies, devices, and digital platforms during National Mental Health Awareness Month. Featured firms include Helus Pharma (HELP), GH Research (GHRS), AtaiBeckley (ATAI), Definium Therapeutics (DFTX), BrainsWay (BWAY), Neuronetics (STIM), and Talkspace (TALK), spanning psychedelic-derived treatments, TMS, and virtual care.